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Abstract
Background: Antibiotic-resistant pathogens are an emerging threat in this century. Epinecidin-1 is a multi-
functional Antimicrobial Peptide (AMP) produced by Orange-spotted grouper (Epinephelus coioides) has been
shown to have extensive potentials as an alternative for current antibiotics. Due to the huge costs for the study and
the production of a new drug, if an antimicrobial peptide has other beneficial functions in addition to antimicrobial
activities, it would be preferred.
Methods: In this study, properties and applications of Epinecidin-1 were investigated and addressed comprehensively.
To achieve this, the Google Scholar search engine and three databases of PubMed, Scopus, and Web of Science
were used.
Results: Epinecidin-1 is a cationic AMP with an alpha-helical structure. Seven functional usages of this peptide
have been reported in the literature including antibacterial, antifungal, antiviral, antiprotozoal, anticancer,
immunomodulatory, and wound healing properties. Moreover, this peptide has high potential to be used as an
active ingredient in cleaning solutions as well as application in vaccine production.
Conclusion: Due to significant antimicrobial activities tested on bacteria such as Staphylococcus aureus and
Helicobacter pylori and also wound healing properties, Epi-1 has high potential to be considered as an important
candidate for the production of new drugs and treatment of various infections including diabetic foot ulcer and
peptic ulcer. Moreover, adjuvant-like properties of Epi-1 make it a suitable candidate for the studies related to an
adjuvant. Other attractive properties such as anticancer effects have also been reported for this peptide which
encourages further studies on this peptide.
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Background
The emergence of antibiotic-resistant pathogens is one
of the main concerns of health organizations in recent
years. Various types of drug resistance are rapidly being
developed for the pathogens while were previously treat-
able using simple antibiotics. However, the introduction
process of new antibiotics is greatly slow. Evidence
shows that the risk of post-antibiotic era is relatively
close to humans [1, 2]. Therefore, finding appropriate
alternatives is highly required.
Antimicrobial Peptides (AMPs) are one of the most
potent alternatives, and many studies have been con-
ducted for them in recent years. They usually have a
short length (less than 50 amino acids), and cell mem-
brane attack is the most known mechanism of their anti-
microbial activity. AMPs are often extracted from a
living organism, or they are peptide derivatives [3]. With
the improvement of bioinformatics science in recent
years, synthetic AMPs have also been designed and
produced. One of the main advantages of these AMPs is
their good antimicrobial effect against multidrug-resist-
ant pathogens. Although these peptides are usually
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known by their antimicrobial effect, they have some
other properties including anti-cancer, immunomodula-
tory, wound healing, and antioxidant effects [3–5].
Aquatic animals are known as a rich source of AMPs
as a part of their innate immunity, and various types of
AMPs have been identified in these organisms [6].
Epinecidin-1 which is a naturally occurring peptide by
orange-spotted grouper (Epinephelus coioides) (Fig. 1)
has been identified since 15 years ago [7]. E. coioides is
one of the common food sources for human especially
in Southeast Asian countries [8].
Up to now, many studies have been performed to
identify the Epinecidin-1 and mechanism of action. In
this review, all studies related to this AMP are investi-
gated with the aim of introducing various classified
aspects of this peptide.
Methods
Search strategy
The search was performed in two steps. First, all English
studies including the Epinecidin-1 AMP (up to March
25, 2019) were selected from PubMed, Scopus, Google
Scholar, and Web of science databases. Only those
original studies were included in our study that helped
to clarify one of the Epinecidin-1 aspects, at least in one
part or the whole of their research.
The search formula (Epinecidin-1[All Fields] OR
Epinecidin-1[All Fields]) AND antimicrobial peptide[All
Fields] was used for PubMed. The search formulas for
Scopus and Web of science were similar to the PubMed
search formula. The keywords of Epinecidin-1, Epi-1,
Epinecidin-1 antimicrobial peptide and Epi-1 antimicro-
bial peptide were used for the Google Scholar search. In
addition, the cited studies to our selected articles and
references were reviewed and studies that could provide
possible additional information on the structure, mech-
anism, and source of Epinecidin-1 were selected.
Results
1. Epinecidin-1
Yin et al. in a study in 2003 made an orange-spotted
grouper leukocyte cDNA library and sequenced more
than 300 expressed sequence tags (ESTs) of cDNA [9].
Three years later, the evaluation and comparison of
these nucleotide sequences with the present AMP
sequences of GenBank database led to the identification
of new AMP which named Epinecidin-1 due to the ex-
traction from E. coioides. cDNA of Epinecidin-1 has 518
bp length (GenBank: AY294407.1), and its largest open
reading frame is 204 bp. Epi-1 is initially synthesized as a
67 amino acids prepropeptide containing three domains
of the signal peptide, mature peptide, and a prodomain.
The Epi-1 gene consisted of three introns and four
exons. Determination of domains and the number of
amino acids have been performed by bioinformatics soft-
ware, as the first 22 amino acids were considered as a
signal peptide and the next 25 amino acids as the
mature peptide [7]. In 2007, Pan et al. considered the
first 21 amino acids as the signal peptide and the next
30 amino acids as the mature peptide. The amino acid
sequence of Epinecidin-1 which introduced as a partial
or full sequence by Yin et al. and Pan et al. are provided
in Table 1. The third sequence of Table 1 was considered
in the subsequent studies in the following years, due to
the lower size and production cost. Investigation of vari-
ous organs of E. coioides showed that the most expres-
sion of this AMP was related to the head, kidneys,
intestines, and skin. While the immunohistochemical
analysis showed that the peptide was localized in the
gills and intestines [10]. This can be explained by the
fact that the expression of Epinecidin-1 is different in
main organs in the pathologic condition. Investigation of
Epinecidin-1 gene expression in the Vibrio harveyi-in-
fected Grouper has shown that expression of this peptide
upregulated by the onset of infection and persisted for ten
days. Interestingly, the highest expression occurred in the
skin followed by gills, liver, and kidney [11].
Investigation of 1182 bp upstream of the Epinecidin-1
gene showed that there were some putative regulatory ele-
ments and binding motifs for transcription factors in this
region. These sequences included TATA box (nucleotide
− 34), three binding sites for CAAT enhancer-binding
protein β (C/EBPβ) (nucleotide − 240, − 554, − 735), and
two binding sites for hepatocyte nuclear factor (HNF) 1
(nucleotide − 667) and HNF-3b (nucleotide − 951). It has
also shown that the Epinecidin-1 production in E. coioides
is increased in exposure to the Lipopolysaccharide (LPS)
and Polyinosinic:polycytidylic acid (poly(I):poly(C)) in a
dose-dependent manner [7, 10, 12].
2. Structure and stability
Comparison of Epinecidin-123-47 with other AMPs
isolated from fish has shown that this peptide has a
71.4–78.6% identity with three peptides of Chrysophsin
1, 2, 3. After chrysophsins, the most identity was related
to Moronecidin (69%), Pleurocidin WF3 (61.9%), and
Piscidin3 (54.5%), respectively [7, 14, 15].
Three derivatives of Epinecidin-1 have a molecular
weight of 2.3–2.9 kDa and are highly cationic (Table 1).
Fig. 1 Orange-spotted grouper (Epinephelus coioides)
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Based on the Schiffer-Edmundson helical wheel diagram,
all three derivatives of this peptide have a secondary
amphipathic α-helix conformation, and polar and
non-polar amino acids are located in two different sides
of structure [7, 16]. Epinecidin-1 has no disulfide bonds
and its alpha-helical structure has been shown well by
the three-dimensional structure provided by protein
structure prediction software (Fig. 2) [17].
The stability of Epinecidin-122-42 antimicrobial effect
was also evaluated under different conditions. Exposure
to Gamma irradiation reduced the antimicrobial effect;
the minimum inhibitory concentration (MIC) was 39 μg/
ml compared to the 9.7 μg/ml of the unirradiated control
after exposing to methicillin-resistant Staphylococcus
aureus (MRSA). Temperature rise also reduced the anti-
microbial activity. The MIC was 312 μg/ml in exposure
to MRSA after 5-min pretreatment at 40 °C compared to
the control group which was 9.7 μg/ml at 25 °C. While
temperature and irradiation showed a negative correl-
ation to antimicrobial activity, acidic conditions had no
significant effect on its activity. The highest activity of
Epinecidin-1 was found under acidic conditions [18].
3. Antibacterial, antifungal, and antiprotozoal effects
AMPs usually have extended-spectrum effects [19]. So far,
Epinecidin-1 antimicrobial activity has been evaluated and
proved on 24 bacterial, six fungal, and one protozoan
strains (Table 2). The MIC value of this peptide is quite
competitive with antibiotics in exposure to many patho-
gens, and it can also kill antibiotic-resistant strains. The
MIC values of three Epinecidin-1 derivatives in exposure
to several pathogens are provided in Table 2.
To evaluate the therapeutic effect of Epinecidin-1 on
Riemerella anatipestifer infection, a study was carried out
in 2009 [20]. This Gram-negative bacterium causes signifi-
cant economic losses as it can infect ducks. Although an
appropriate antibiotic treatment exists for this infection,
antibiotic resistance is being increased [21, 22]. Investiga-
tion of Epinecidin-1 therapeutic effect on R. anatipestifer
infected ducks as pretreatment, co-treatment, and
Table 1 Epinecidin-1 derivatives and their characteristics
Study Epi-1 derivative peptide sequence Location in Epi-1 prepropeptide pI [13] Charge [13] MW [13]
Yin et al. [7] FIFHIIKGLFHAGKMIHGLVTRRRH 23–47 12.811 + 5 2985.64134
Pan et al. [10] GFIFHIIKGLFHAGKMIHGLVTRRRHGVEE 22–51 11.426 + 3 3457.10874
GFIFHIIKGLFHAGKMIHGLV 22–42 10.591 + 2 2335.88454
Fig. 2 The spatial organization of Epinecidin-1 derivatives. Helical wheel diagrams (up) [7, 16], three-dimensional structure (down) [17]
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[10, 18, 20, 28, 29, 31]
Gram-positive bacteria Listeria monocytogenes (BCRC14930) – 25 50
Bacillus subtilis > 200 – –
Micrococcus luteus (BCRC11034) – 3.125 25
Staphylococcus aureus (BCRC10780) – 6.25 9.7–12.5
Streptococcus pyogenes (BCRC10797) – 25 25
Streptococcus agalactiae (819) – 12.5 50
Staphylococcus epidermidis (BCRC10783) – 12.5 > 100
Staphylococcus sp. (BCRC10451) – 6.25 50
Staphylococcus xylosus (BCRC12930) – > 100 50
Streptococcus pneumoniae (BCRC10794) – 12.5 25
Staphylococcus aureus subsp. (BCRC10782) – 6.25 6.25
Propionibacterium acnes – – 200
Gram-negative bacteria Helicobacter pylori – – 8–12
Enterobacter aerogenes (BCRC10370) – 25 50
Enterobacter cloacae subsp. (BCRC10401) – 100 100
Vibrio alginolyticus – 12.5 100
Klebsiella oxytoca (BCRC13985) – 25 50
Salinivibrio costicola subsp. (BCRC12910) – 3.125 12.5
Vibrio parahaemolyticus < 0.4 – –
Vibrio vulnificus (YJ016) – 3.125 12.5
Vibrio harveyi (BCRC13812) – 3.125 12.5
Vibrio harveyi (BCRC12907) – 6.25 12.5
Vibrio vulnificus 12.5 6.25 12.5
Vibrio alginolyticus (BCRC12829) 0.77 6.25 12.5
Pasteurella multocida 0.77 – –
Morganella morganii 0.77 – –
Aeromonas sobrio 3.11 – –
Aeromonas hydrophila 3.11 – –
Escherichia coli 6.24 – –
Pseudomonas aeruginosa – > 100 60
Pseudomonas fluorescens 200 – –
Yersinia enterocolitica subsp. (BCRC13999) – 100 100
Flavobacterium meningosepticum < 0.4 – –
Riemerella anatipestifer (11 different strains) – – 6.25–50 (Average 27.8)
Other Trichomonas vaginalis (ATCC 50143) 25–62.5
Trichomonas vaginalis – – 12.5
Candida albicans 25 – 25
Pichia pastoris 495 – –
Microsporosis canis 50 – –
Trichophytonsis mentagrophytes 100 – –
Cylindrocarpon sp. 100 – –
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post-treatment showed that the number of bacteria in
duck greatly reduced in all three cases and the survival
rate was significantly increased [20]. Study of two aquatic
animals of tilapia (Oreochromis mossambicus) and grouper
to reveal the therapeutic effect of Epinecidin-1 in Vibrio
vulnificus infection showed that the simultaneous
injection of bacteria and peptide significantly increased
their survival. The half-life of this peptide in tilapia was
60–80min following the injection [10]. In a study on V.
vulnificus contaminated fish using zebrafish model system,
it was shown that the pretreatment, co-treatment, and
post-treatment with 1 μg of Epinecidin-1 could increase
the survival rate of fish from 3 to 56.6%, 80, and 60%
respectively [23].
Epinecidin-1 showed good bactericidal effects when
exposed to sensitive and antibiotic-resistant Pseudo-
monas aeruginosa. The mouse model infected by
multidrug-resistant P. aeruginosa strains also combated
the infection more effectively with no adverse behavioral
effects, hepatotoxicity, and nephrotoxicity when
Epinecidin-1 applied [24, 25].
Helicobacter pylori is a gram-negative bacterium that
causes active chronic gastritis and may cause complica-
tions such as malignancies, dyspepsia, and peptic ulcer
[26]. The H. pylori infection is very important as the
Nobel Prize in physiology in 2005 was awarded for the
discovery of the peptic ulcer disease caused by an infec-
tion with H. pylori [27]. Following the development of
antibiotic-resistant H. pylori strains, evaluation of AMPs
has started for the treatment of this infection.
Epinecidin-1 is one of the most potent AMPs which
have been introduced so far [5]. This peptide can inhibit
the growth of sensitive and antibiotic-resistant H. pylori
strains with the MIC of 8–12 μg/ml. It has also shown
that the oral administration of Epinecidin-1 (250 μg)
could completely remove the H. pylori from the stomach
in a C3H/HeN mice [28].
In a study performed in 2019 on mice, suffering
from metronidazole-resistant trichomoniasis, it was
reported that Epinecidin-1 could combat the infec-
tion effectively [29]. Trichomoniasis is a sexually
transmitted disease caused by a protozoan called
Trichomonas vaginalis. More than 140 million people
worldwide are annually affected by this infection
[30]. In two studies, the Epi-1 MIC has been
reported as 12.5 μg/ml and 25–62.5 μg/ml for
metronidazole-sensitive and -resistant strains of T.
vaginalis, respectively [29, 31]. It has also shown that
a 400 μg dose should be used for the complete elim-
ination of infection in mice with trichomoniasis. A
remarkable point of this report is that no damage
was observed in vaginal epithelial cells of mice in
500 and 1000 μg doses. It can be attributed to the
protective mucus layer on these cells [29].
4. Antiviral effect
Antiviral effects of many AMPs have been reported so
far. However, according to the Antimicrobial Peptide
Database (APD), antiviral effects have been evaluated
and reported for only 185 out of more than 3000
registered AMPs. It should be noted that regarding the
more difficult evaluation of antiviral properties, most of
the AMPs have not been evaluated for these effects.
Fortunately, Epinecidin-1 is among the AMPs with well
investigated antiviral properties [3, 32].
Betanodavirus or nervous necrosis virus (NNV) is a
virus classified in the Nodaviridae family. It is one of the
main fish pathogens which causes much damage in cul-
tured marine fishes each year [33]. Effect of Epinecidin-1
on this virus has been investigated in two studies. Wang
et al. investigated the effect of Epinecidin-1 (1, 0.5, 0.1,
and 0.05 μg) with pretreatment, post-treatment, and
co-treatment on E. coioides infected by NNV and the
best result was related to the co-treatment.
Co-treatment of Epinecidin-1 and NNV through the
anal canal could increase the survival rate of infected
fish in a dose-dependent manner. For example,
co-treatment of 1 μg/fish Epinecidin-1 ten minutes
before the virus inoculation could increase the survival
rate from 11 to 35% [34]. In another study, the maximal
non-cytotoxic concentration of Epinecidin-1 to GF-1
and cBB cells was determined as 4 and 8 μg/ml, respect-
ively. Therefore, the evaluation of Epinecidin-1 antiviral
effects should be performed at lower concentrations. In-
vestigation of Epinecidin-1 antiviral effect on nervous
necrosis virus (NNV) in non-cytotoxic concentration for
these two cell lines showed that this peptide was not
able to completely block the virus infectivity [35],
although it has been shown to be possible in higher
concentrations [34].
The foot-and-mouth disease virus (FMDV) is a
member of the picornavirus family and Aphthovirus
genus that can cause foot-and-mouth disease in
cloven-hoofed animals and is highly contagious.
Although it has a low mortality rate, it can cause
significant losses for animal husbandry in low milk
and meat production as well as animal products [36].
In a study by Huang et al. in 2018 on the evaluation
of the antiviral effects of five marine AMPs, it was
observed that Epinecidin-122-42 could combat FMVD
more effectively. The BHK-21 cells were used in their
study. The 50% cytotoxic concentration (CC50) of
Epinecidin-1 for BHK-21 cells was 19.5 μg/ml and the
50% effective concentration (EC50) for viral inhibition
was 0.6 μg/ml. Investigation of higher concentrations
(10 × EC90 of Epinecidin-1) showed good virucidal
activity against FMDV. It was also observed that the
most effect of this peptide was during the viral
adsorption stage [37].
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Japanese encephalitis virus (JEV) is a flavivirus that
causes encephalitic diseases in children [38]. It has
shown that co-treatment of 1 μg/ml Epinecidin-1 plus
JEV on BHK-21 cells, dropped the infection rate by 50%
compared to the control. Also, a study on mouse model
showed that with the co-injection of JEV and 200 μg/ml
Epinecidin-1, all mice survived. However, the group of
mice without Epinecidin-1 co-injection were died [39].
Evaluation of the gene expression of Epinecidin-1
under different conditions showed that the infection by
Singapore grouper iridovirus (SGIV) up-regulated the
Epinecidin-1 gene in E. coioides [40].
5. Anticancer effect
Most of the current cancer treatment methods are com-
plex and have side effects. For example, chemotherapy
causes serious side effects. Also, current anticancer
drugs are often focused on the destruction of cells with
a high rate of growth, and probably they are not able to
differentiate between cancer and normal cells. In
addition, the emergence of multidrug-resistant cancer
cells which are capable of neutralizing the function of
anticancer drugs is a new challenge. This happens
through various mechanisms including repair of
damaged DNA, transport of the drug out of the cell, and
expression of drug detoxifying enzymes [41, 42]. Conse-
quently, the focus of most of the studies was on the anti-
cancer properties of various types of natural or chemical
drug compounds. In recent years, with the increased
research on AMPs, it has been observed that some of
them also have anticancer effects. Epi-1 is one of the
AMPs with reported anticancer properties in several
studies [42, 43].
Anticancer AMPs are usually divided into two
groups. The first group can kill cancer cells as well as
normal mammalian cells. The second group is potent
to kill cancer cells, while no activity against normal
mammalian cells or with poor activity [44]. A study
on the Epinecidin-1 cytotoxic effect on some normal
and cancer cells showed that this peptide could ef-
fectively inhibit the growth of both tumor and normal
cell lines at the concentrations above 2.5 μg/ml.
Although the growth inhibition also occurred for
normal cells, the rate of inhibition at the 2.5 μg/ml
concentration was slightly lower for the normal cells
(AML-12, NIH3T3, and WS-1) compared to the can-
cer cells (A549, HA59T/VGH, HeLa, HT1080,
RAW264.7, and U937). It has also shown that the
Epinecidin-1 induces cytotoxic effects and membrane
lysis through the perturbation of the cancer cell
membrane. Also, this peptide inhibits the necrosis in
HT1080 cells (highly aggressive fibrosarcoma cell line)
by downregulating the necrosis-related genes [45].
In another study, it was shown that Epinecidin-1
inhibited the proliferation and induced the apoptosis in
human leukemia U937 cells. This seemed to occur
through the increase in tumor necrosis factor (TNF)-α;
interleukin (IL)-10, interferon (IFN)-γ, p53, IL-15, and
IL-6. It was also observed that the ADP/ATP ratio which
is an indication of mitochondrial dysfunction, was in-
creased in these cells [46].
To date, there is not much research to clarify the exact
mechanism of Epinecidin-1 anticancer function. How-
ever, it should be noted that the AMPs with a similar
structure to Epinecidin-1 usually have the same antican-
cer mechanism [47]. Generally, a cancer cell is involved
in the events that lead to an increase in the net negative
charge of the cell surface. The cationic peptides are
absorbed to this negatively charged cells, then the
destruction of the cancer cell would occur. Although the
normal cells usually have lower negative charges in the
surface membrane, the cancer cells express many an-
ionic molecules including phosphatidylserine (PS), sialic
acid, membrane-associated glycoproteins, chaperone
proteins HSP90 and GRP78 [42].
6. Wound healing effect
Epithelial cell proliferation and migration are two
important factors in wound healing [48]. The effect of
Epinecidin-1 has been recently evaluated on these
factors using immortalized keratinocyte HaCaT cells.
Epinecidin-1 did not show any cytotoxic effects on these
cells at the concentration of 31.25 μg/ml. It is interesting
that the treatment of cells with 15.625 μg/ml
Epinecidin-1 resulted in increased cell numbers and pro-
portions of actively dividing S-phase cells out of the total
cells. So it can be concluded that the treatment with
Epinecidin-1 promoted the cell proliferation and migra-
tion into the wounded region [49].
Furthermore, animal studies on MRSA-infected skin
ulcers in mice and swine indicated that this peptide
reduced the bacterial count in the wounded region,
increased the angiogenesis, and enhanced wound
closure [49, 50].
In a mouse model with MRSA-infected skin ulcer, use
of Epinecidin-1 resulted in faster wound closure
compared to the non-infected ulcers and infected but
vancomycin-treated ulcers. Also, co-treatment with
Epinecidin-1 and collagen enhanced the healing and
re-epithelialization compared to Epinecidin-1 treatment
alone. Evidence shows that Epinecidin-1 activity in
MRSA-infected ulcers is not only related to the anti-
microbial property, and this peptide also plays a role in
the regulation of some cytokines. For example in
MRSA-infected mice ulcers, treatment with Epinecidin-1
decreased serum levels of the proinflammatory cytokines
TNF-α, IL-6, and MCP-1, and regulated the recruitment
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of monocytes and clearance of lymphocytes around the
wounded region during healing [49].
In confirmation of previous findings, the results of
another study on the effect of Epinecidin-1 on the
healing of MRSA-infected swine burn ulcers showed
that this peptide could accelerate the wound healing and
provide protection against infection. Within 25 days,
Epinecidin-1 increased epithelial activities, extracellular
collagen compound formation, and vascularization. Also,
treatment of swine with Epinecidin-1 suppressed the
C-reactive protein (CRP) and the pro-inflammatory
cytokine IL-6, while their expression induced in un-
treated swine group [50].
7. Mechanism of action
In this section, the discovered mechanisms of action of
this peptide are introduced. In most studies, there are
two main mechanisms involved to combat the infec-
tions, including (i) Direct attack on the cell membrane
of pathogens (ii) Regulation of the immune system to
combat infection.
Membrane attack
The main invasive mechanism of this peptide in expos-
ure to pathogens is the destruction of the cell membrane
[20, 31]. It has been observed that Epinecidin-1 reduces
the negative surface charge following the binding to the
bacterial surface. This peptide causes the saddle splay
membrane curvature generation in bacterial membrane
followed by pore formation, blebbing, budding, and
vesicularization in membrane and lysis. Membrane lysis
results in bacterial death [28, 46]. For example, the
appearance of three pathogens of Candida albicans,
Propionibacterium acnes, and Trichomonas vaginalis in
exposure to Epinecidin-1 were evaluated in one study
using scanning electron microscopy (SEM) and trans-
mission electron microscopy (TEM). The comparison of
their appearance before and after Epinecidin-1 treatment
showed that this AMP caused breakage in the mem-
brane and intracellular contents were transported out-
side the cell. C. albicans was also found to have a highly
irregular shape, in addition to the membrane breaks.
The morphological changes of Trichomonas were as
membrane destruction and hollow appearance [31]. An-
other study evaluated the Epinecidin-1 effect on 11
strains of R. anatipestifer which is a pathogen of ducks,
and it was shown that this peptide caused breaks in the
membrane and the efflux of cellular contents [20]. Fur-
thermore, observation of Epinecidin-1 effects on P.
aeruginosa using TEM revealed membrane disruption
and lighter electron density in the cytoplasm [25].
Fortunately, the toxic concentration threshold for
human cells is much higher than the microbial cells.
Epinecidin-1 at the concentration of 0.42 μM have no
hemolytic effect on human RBCs. However, hemolytic
effects appear to be highly dose-dependent at the
0.83 μM concentration [7, 29]. High doses of
Epinecidin-1 did not exert toxic effects in oral, dermal,
and eye irritation models [28].
Immune regulation
It has been shown in many studies that Epinecidin-1
combat infections through the regulation of the immune
system. In Japanese encephalitis virus infection,
Epinecidin-1 modulated the expressions of MCP-1, IL-6,
IL-10, IFN-γ, TNF-α, and IL-12, and elevated the levels
of anti-JEV-neutralizing antibodies in the serum [39].
It was also shown that Epinecidin-1 could play a role in
the regulation of Mx2 and Mx3 genes expression [34, 35].
It should be noted that Mx genes exist in the genome of
most vertebrates are responsible for a specific antiviral
state against viruses [51]. In V. vulnificus-infected fish,
Epinecidin-1 could also regulate immune response genes
such as IL-10, IL-1b, TNF-α, and IFN-γ and help to con-
trol the infection by enhancing the immunity [23].
Co-injection of Epinecidin-1 and P. aeruginosa in a
mouse model showed that this peptide was a good im-
munomodulator. Epinecidin-1 induced significant secre-
tion of immunoglobulin G1 (IgG1) through the
activation of Th2 cell response in infected mice. Treat-
ment with this peptide during the septic shock also had
a positive effect and probably involved protecting the
liver against LPS-induced dysfunction and preventing
damage to several other organs in septic mice [24].
In a study of immunostimulatory effect of Epinecidin-1
peptide in two models of grouper (E. coioides) and
zebrafish (Danio rerio), it was shown that this peptide sig-
nificantly increased the expression of some important
genes of immunity such as (TNF)-1 in grouper and
Toll-like receptor (TLR)4, IL-1b, nitric oxide synthase
(NOS)2, and (NF)-κB in zebrafish [52].
According to these findings, researchers aimed to
produce recombinant Artemia (a live feed for fry in
aquaculture) to express Epinecidin-1. It was observed
that supplementing adult or larva fish especially zebra-
fish with this transgenic Artemia strain, significantly
increased the immunity against infections [53, 54].
In the study of mice peritonitis infection caused by
P. aeruginosa ATCC 19660, it was shown that Epine-
cidin-1 decreased the concentrations of IL-1β, IL-6, and
TNF-α. Interestingly, if the peritonitis caused by the resist-
ant strains of P. aeruginosa, Epinecidin-1 treatment sig-
nificantly increased plasma concentrations of IL-1β and
TNF-α [25]. Epinecidin-1 in Raw264.7 macrophage cells
could inhibit the inflammation through the LPS
neutralization. It could also directly inhibit MyD88 via in-
duction of the Smurf E3 ligase proteasome pathway.
MyD88 is a protein that functions as an essential signal
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transducer in the IL-1 and TLR signaling pathways. These
pathways regulate the activation of numerous proinflam-
matory genes. It is notable that LPS upregulates the
MyD88 protein level [55, 56].
Epinecidin-1 also have been shown to combat H.
pylori infection through immunologic changes in the
host. For example, inhibited infection through in vivo
depletion of CD4 + -FOXP3+ T Regulatory and Th17
subset populations, and aided in clearance of persistent
H. pylori colonization. Flow cytometry and gene expres-
sion analysis of mouse splenic and gastric tissue
indicated that Epinecidin-1 inhibits IL-10, and thereby
affects FOXP3 expression levels and reduces
pro-inflammatory cytokine responses [28].
In a duck model infected by R. anatipestifer, it was
shown that Epinecidin-1 injection produced upregulated
expression of the Mn superoxide dismutase (MnSOD)
gene in brain tissue [20]. This gene plays an important
role in host defense against the oxidative damage due to
the infection-mediated inflammation [57].
8. Application of Epinecidin-1 in vaccine design
There is evidence of AMPs adjuvant properties that have
made them suitable candidates for further studies.
Adjuvant-like properties of AMPs have been reported
for the Epinecidin-1 in several studies [58]. The
co-treatment of Epinecidin-1 with V. vulnificus showed
vaccine-like effects in addition to therapeutic effects. As
the surviving zebrafish after 30 days of co-treatment
were re-challenged with V. vulnificus and a survival rate
of 45% was observed, while this rate was about 3% in the
control group [23].
Similar properties have also been reported for the
advantages of using Epinecidin-1 in vaccine production.
As mentioned in section 4, co-injection of Epinecidin-1
with JEV virus prevented the death in mice. Interest-
ingly, with the re-challenge of surviving mice of the pre-
vious step, all mice survived. While the unvaccinated
control group did not survive. In the study of cytokines,
it was found that Epinecidin-1 induced higher levels of
Th2 cytokine than Th1 cytokine [39]. Similar results
were obtained regarding the NNV-infected fish as well.
When Epinecidin-1 treated fish were subjected to
re-challenge with the co-treatment of Epinecidin-1 and
NNV, the survival rate was even higher [34].
A report in 2012 showed that 30-day oral administra-
tion of Epinecidin-1 in two marine models of zebrafish
and E. coioides exhibited excellent inhibition of bacterial
growth against V. vulnificus [52].
9. Epinecidin-1 as a part of cleaning solutions
Cleaning solutions have broad applications in commu-
nity hygiene. Usually, various antimicrobial agents are
added to increase the microbicidal effects, such as
pyrophosphate, zinc citrate, silicon oil, benzalkonium
chloride, and cocamidopropyl betaine (CAPB). Unfortu-
nately, it has been observed that the addition of these
compounds could correlate with the emergence of resist-
ant strains to antibiotics and disinfectants. Further re-
search, therefore, is required to test new compounds
[59, 60]. Epinecidin-1 is one of the few AMPs in which
the efficiency has been evaluated as a part of the clean-
ing solution. It has shown that combination of this pep-
tide with commercial cleaning solutions could
significantly reduce the count of six pathogens including
Enterococcus faecalis, Escherichia coli, P. aeruginosa, S.
aureus, Propionibacterium acnes, and C. albicans, com-
pared to the control. It has also been reported that pa-
rameters such as low temperature and pH have no
significant effect on the Epinecidin-1 bactericidal activity
in cleaning solutions. Therefore, it is possible to consider
this AMP for combination with various disinfectants in
the future [61].
Discussion
The common property of all AMPs is to have lethal
effects against one or more types of microbes (such as
bacteria, virus, and protozoa). A factor that promotes
the superiority of an AMP over others is a robust
multi-functional activity. Regarding this issue, a strong
bactericidal AMP with other activities such as immuno-
modulatory and anticancer features can be considered
for research as an appropriate drug candidate [62]. In
addition to antimicrobial activities of Epinecidin-1 on a
wide range of microbes (bacteria, fungi, virus, and
protozoa), other functions have been reported such as
immunomodulatory, wound healing, and anticancer
effects. LL-37 and Pexiganan are among the most known
multi-functional AMPs that have been introduced so far.
LL-37 is currently in Phase-II clinical trials for the
treatment of Venous leg ulcers (VLUs) [63]. Pexiganan
have also been evaluated clinically as a topical treatment
for diabetic foot ulcer [64].
New and on-going findings associated with
Epinecidin-1 encouraged us to write a comprehensive
review of all previous studies on this peptide with high
therapeutic potential to pave the way for further studies.
Epinecidin-1 is a cationic AMP with an alpha-helical
structure. Similar to other cationic properties (structure
and function), alpha-helical AMPs can absorb to the
bacterial surface due to the positive charge. The
structure and positive charge made this AMP very simi-
lar to LL-37 and Pexiganan [65].
Although many studies have been performed on this
peptide, some characteristics are still not fully under-
stood. The authors suggest the following arguments to
be considered in future studies:
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1. Investigation of exact anticancer mechanisms on a
broader range of cancer cells.
2. Assess the possibility of producing topical drugs for
the treatment of various infectious wounds, in
particular, drug-resistant types.
3. This peptide has very powerful anti-Helicobacter
pylori effects [34]. So, it can be considered for the
treatment of such infections.
4. AMPs can have several functions, some of which
have not been investigated for Epinecidin-1 yet.
Therefore, evaluating other features such as
antioxidant, anti-insect, protease inhibitor,
spermicidal, and antitoxin effects can be considered.
5. A more comprehensive review of the toxicity and
side effects of this peptide, especially on the intact
animal.
Conclusion
Epinecidin-1 is a strong multi-functional AMP with
seven known functions including antibacterial, antifun-
gal, antiviral, antiprotozoal, anticancer, immunomodula-
tory, and wound healing activities. This peptide has high
potential for further research and application in new
drugs.
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